This image provided by Biogen on Monday, June 7, 2021 shows a vial and packaging for the drug Aduhelm. The first new Alzheimer’s treatment in more than 20 years was hailed as a breakthrough when regulators approved it in June 2021, but its rollout has been slowed by questions about its price and how well it works. Credit: Biogen via AP, File
A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, extending a slow debut complicated by coverage questions and doctor concerns.
The infused drug, hailed as a potential breakthrough treatment for a fatal disease, has encountered a health care system that “remains…
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...
